NanoPhoria
NanoPhoria is a preclinical-stage biotechnology company developing a proprietary Nano-in-Micro delivery platform based on inorganic Calcium Phosphate (CaP) nanoparticles. The technology enables tissue-directed treatment for patients with cardiovascular conditions via an inhaled delivery route. Its primary therapeutic focus is addressing Heart Failure with Reduced Ejection Fraction (HFrEF).
Visit websiteMilan, Italy
Biotechnology
Healthcare
Cardiovascular
Funding summary
- Total raised
- €83.5M
- Funding rounds
- 1
Investors in NanoPhoria
Investors on record for NanoPhoria. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like NanoPhoria?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors